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ABSTRACT Asthma often remains uncontrolled, despite the fact that the pharmacological treatment has
undergone large changes. We studied changes in the treatment of asthma over a 20-year period and
identified factors associated with the regular use of inhaled corticosteroid (ICS) treatment.
Changes in the use of medication were determined in 4617 randomly selected subjects, while changes in
adults with persistent asthma were analysed in 369 participants. The study compares data from three
surveys in 24 centres in 11 countries.
The use of ICSs increased from 1.7% to 5.9% in the general population and the regular use of ICSs
increased from 19% to 34% among persistent asthmatic subjects. The proportion of asthmatic subjects
reporting asthma attacks in the last 12 months decreased, while the proportion that had seen a doctor in
the last 12 months remained unchanged (42%). Subjects with asthma who had experienced attacks or had
seen a doctor were more likely to use ICSs on a regular basis.
Although ICS use has increased, only one-third of subjects with persistent asthma take ICSs on a
regular basis. Less than half had seen a doctor during the last year. This indicates that underuse of ICSs
and lack of regular healthcare contacts remains a problem in the management of asthma.
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Despite increased ICS use, only 34% of subjects with persistent asthma take ICSs on a regular
basis; <50% have seen a doctor in the last year. Underuse of ICSs and lack of regular healthcare
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Introduction
The pharmacological treatment of asthma has undergone large changes during the last two decades with
new treatment options such as long-acting β2-agonists (LABAs), leukotriene antagonist (LTRAs), fixed
combinations of inhaled corticosteroids (ICSs) and LABAs (ICS+LABA), long-acting muscarinic receptor
antagonists (LAMAs), anti-IgE, and anti-interleukin (IL)-5 therapies. International guidelines have been
available since the 1990s and are continuously updated with regular use of ICSs as the cornerstone of
first-line treatment of asthma [1]. Despite this there are reports showing that asthma remains uncontrolled
in a large proportion of patients [2–4], still has a large effect on quality of life [5, 6], influences patients’
sleep [7, 8] and causes a large economic burden for society [9, 10].
The European Community Respiratory Health Survey (ECRHS) is a unique study where participants from the
general population in a large number of countries have been surveyed 3 times over a 20-year period [11, 12].
At the first ECRHS survey (ECRHS I), large differences were found regarding the prevalence of asthma
therapy, with an 8-fold difference in the use of ICSs among countries [13]. In the second survey (ECRHS II)
there was an increase in the use of ICSs, but despite this only 17% of participants with asthma were using
ICSs on a daily basis [14]. Analyses from the first two time-points showed that females with asthma were
more likely and smokers with asthma less likely to use ICSs than males and nonsmokers, respectively
[14, 15]. A surprisingly low use of ICSs on a daily basis in asthmatic subjects has also been found in other
studies [4, 16]. Change in medication is influenced by longitudinal change in the prevalence of asthma and
asthma symptoms. Longitudinal studies of asthma and asthma symptoms in adults have shown diverging
results, with an increase in self-reported asthma and asthma symptoms with age in an English and a
Canadian study [17, 18], and a decrease in the prevalence of asthma symptoms in a German study [19].
There are, however, very few studies of longitudinal change in the pharmacological treatment of asthma and
such studies are needed in order to optimise the therapeutic management of asthma at the population level.
The third survey of the ECRHS (ECRHS III) was completed between 2011 and 2014. An analysis of data
from a short postal questionnaire showed an increase in the use of asthma medication [20]. The aim of the
present study was to undertake a more detailed investigation of changes in the pharmacological treatment
of asthma over a 20-year period and to investigate factors associated with the regular use of ICSs.
Methods
Population
The designs of ECRHS I and II have been described in detail [21, 22]. In ECRHS I, each participant was
sent a brief questionnaire (stage 1) and from those who responded, a random population-based sample
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was selected to undergo a more detailed clinical examination. In addition, a “symptomatic sample”,
reporting been woken by an attack of shortness of breath, asthma attacks or using asthma medication in
stage 1, was also invited to the same clinical examination. This examination included spirometry, allergy
testing and a structured interview. In ECRHS II, subjects who had participated in the clinical phase of
ECRHS I were invited to participate in the follow-up. The clinical phase of ECRHS I and II was
performed during 1991–1994 and 1998–2002, respectively. ECRHS III is the second follow-up and was
performed from February 2011 to January 2014 [23]. The numbers of participants in the various parts of
ECRHS I–III are presented in figure 1.
Only participants from the random sample were included when describing change in the prevalence of use
of medication and geographical difference in the general population. The participants who had originally
been selected as part of the random or the symptomatic sample were included when analysing medication
in subjects with persistent asthma.
Centres and countries
This investigation included 24 centres from 11 countries: Iceland (Reykjavik), Norway (Bergen), Sweden
(Gothenburg, Umeå and Uppsala), Estonia (Tartu), Germany (Erfurt and Hamburg), UK (Ipswich and
Norwich), Belgium (Antwerp), France (Bordeaux, Grenoble, Montpellier and Paris), Spain (Albacete,
Barcelona, Galdakao, Huelva and Oviedo), Italy (Pavia, Torino and Verona) and Australia (Melbourne).
Questionnaire
The subjects underwent a structured interview asking for detailed information on respiratory symptoms,
asthma and asthma therapy. Pictures, samples or lists of different asthma medications were shown to
facilitate a correct answer to the therapy questions.
Definition of asthma-related variables
Physician-diagnosed asthma: a positive answer to the questions “Have you ever had asthma?” and “Was
this confirmed by a doctor?”.
Asthma-related symptoms in the last 12 months: reported having had wheeze, nocturnal chest tightness or
attacks of breathlessness following activity, at rest or at night during the last 12 months.
Current asthma: having physician-diagnosed asthma and having had at least one of the following criteria:
asthma-related symptoms, attacks of asthma in the last 12 months or reported current use of any
medicines for asthma.
Persistent asthma: having current asthma at all three surveys.
The participants were also asked whether they had asthma attacks within the last 12 months and if “yes”,
the number of attacks.
FIGURE 1 Selection of population.
ECRHS: European Community Res-
piratory Health Survey.
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Medications for asthma
Participants were considered to be taking medication for asthma if they reported having used any of the
following drugs for their breathing in the 12 months preceding each survey: 1) inhaled asthma medications
(short-acting β2-agonists (SABAs), LABAs, short-acting muscarinic receptor antagonists, LAMAs and
ICSs), 2) oral asthma medications (β2-agonists, theophylline, LTRAs and oral corticosteroids (OCSs)) and
3) injections for the treatment of allergy (including omalizumab). Patients who used fixed combinations of
ICS+LABA were considered to be using both drugs. Patients that reported having used ICSs
“continuously” in the last 3 months before each survey were defined as regular users of ICSs.
Healthcare utilisation
The participants were asked whether they had spent a night in hospital and whether they had been seen
by a doctor because of breathing problems in the 12 months preceding each survey.
Smoking, chronic obstructive pulmonary disease, educational level and body mass index
Current smoker was defined by answering yes to the two questions “Have you ever smoked for as long as a
year?” and “Do you now smoke, as of 1 month ago?”. In ECRHS III the participants were asked whether a
doctor ever told them that they have chronic obstructive pulmonary disease (COPD). Information on
educational level was collected in ECRHS I and a low education level was defined as having completed
full-time education before the age of 16 years [14]. Body mass index (BMI) was calculated from height and
weight recorded in all three surveys.
Ethics approval
Local ethics committees at each centre approved the study protocols. All participants provided written
informed consent.
Statistics
All statistical analyses were conducted using Stata version 14 (StataCorp, College Station, TX, USA).
Absolute net changes in medication, asthma attacks and healthcare utilisation between the surveys were
estimated using population-averaged, generalised estimating equations for a binomial outcome with
identity link, with participants identified as the clustering factor and the number of the survey as an
independent variable. Results were expressed as net percentage change between surveys. The Wald test was
used to examine differences in change of prevalence by survey. Estimated changes in treatments by
country were examined for heterogeneity and combined using random effects meta-analyses.
The Chi-squared test was used when comparing the prevalence of medication between countries in
cross-sectional analyses. Spearman’s correlation test was used when analysing the ecological association
between the prevalence of current asthma and the prevalence of the use of medication for asthma.
We assessed the influence of several personal and asthma characteristics on the regular use of ICS
treatment among subjects with persistent asthma. The associations were estimated using mixed effects
logistic regressions with the participant as the clustering unit to account for the repeated measurements.
The factors assessed were chosen based on previous experience [14], and included age, sex, BMI, smoking,
educational level, doctor visits, hospitalisations, asthma attacks, survey and country. Only variables with a
p-value <0.1 in the unadjusted analyses were included in the final model.
Results
Use of medications for asthma in the random population sample
The random sample included 4617 subjects (52.1% female) that were seen at all three surveys. The
mean±SD age at ECRHS I was 34.4±7.1 years and the mean follow-up was 20.1 years. Those who
participated in all three surveys were less likely to be smokers (32.7% versus 39.8%), were slightly older
(mean±SD age 34.4±7.1 versus 33.2±7.2 years; p<0.0001) and had used SABAs more often (4.8% versus
3.6%; p=0.003) at ECRHS I than those that only participated in the first survey. No significant difference
was found in sex and BMI distribution or use of ICSs between those that participated in all three surveys
and those that only participated in the first survey (data not shown).
The prevalence of use of medication for asthma had almost doubled from 5.2% to 9.9% between ECRHS I
and III (table 1). A significant increase was found for all inhaled compounds as well as LTRAs and OCSs,
while a significant decrease was found for theophylline. Changes in the use of ICSs between ECRHS I and
III by country are presented in figure 2. A significant increase was found in most countries. There was
significant heterogeneity between countries.
In the random sample, 43 (0.9%) participants reported that they had a diagnosis of COPD. Excluding
these subjects had only a marginal effect on the prevalence of use of pharmacological treatment. As an
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example, the prevalence of use of ICSs decreased from 5.9% to 5.5% and the corresponding values for
SABAs were from 6.2% to 5.9%.
The highest prevalence of current asthma and medication use for asthma in ECRHS III was found in
Australia and the lowest in Belgium (table 2). There were statistically significant differences between the
countries in the use of SABAs and LABAs, but not in the use of ICSs. There was a strong statistical
ecological association between the prevalence of current asthma and the prevalence of use of any
medication for asthma, whereas no significant association was found between the prevalence of asthma
and the prevalence of ICS use (figure 3).
TABLE 1 Use of medication during the last 12 months in the random sample#
ECRHS I ECRHS II ECRHS III Change in prevalence
Inhaled SABAs 3.6 5.7 6.2 2.7 (2.0–3.4)
Inhaled LABAs¶ 1.2 4.2 3.0 (2.4–3.6)
ICSs¶ 1.7 4.0 5.9 4.2 (3.5–4.9)
ICS+LABA 0.9 3.8 2.9 (2.4–3.5)
Inhaled anticholinergics 0.2 0.2 0.5 0.3 (0.07–5.1)
Theophylline 0.7 0.2 0.1 −0.6 (−0.9–−0.4)
Oral b2-agonists 0.4 0.3 0 −0.4+
LTRAs 0.2 0.6 0.4 (0.2–0.7)
OCSs 0.6 1.1 1.0 0.4 (0.1–0.8)
Any medication for asthma 5.2 8.0 9.9 4.8 (3.9–5.6)
Data are presented as %, and change between European Community Respiratory Health Survey (ECRHS) I
and III in % (95% CI), or in case of absence of information from ECRHS I, change between ECRHS II and
ECRHS III in % (95% CI). SABA: short-acting b2-agonist; LABA: long-acting b2-agonist; ICS: inhaled
corticosteroid; LTRA: leukotriene receptor antagonist; OCS: oral corticosteroid. #: n=4617; ¶: as a single
inhaler or in combination; +: not possible to calculate 95% confidence interval.
Overall  (I2=61.9%, p=0.005)
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Country
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Italy
Sweden
4.30 (3.63–4.96)
2.69 (–0.16–5.55)
3.52 (0.97–6.08)
5.19 (2.83–7.54)
3.15 (1.76–4.55)
5.18 (3.59–6.77)
5.34 (2.81–7.86)
Change
% (95% CI)
6.62 (4.37–8.87)
1.07 (–1.48–3.62)
5.77 (4.07–7.47)
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FIGURE 2 Change in the use of inhaled corticosteroids (as a single inhaler or in combination; any use in the
last 12 months) in the random sample between European Community Respiratory Health Survey (ECRHS) I
and III analysed by country and combined in a meta-analysis. Analysis was not possible for Estonia due to the
limited number of participants. The area of each square is proportional to the reciprocal of the variance of the
estimate for the country. The combined random effects estimate is shown by the dashed line; the width of the
diamond is the 95% confidence interval.
https://doi.org/10.1183/23120541.00073-2018 5
ASTHMA | C. JANSON ET AL.
Treatment in subjects with persistent asthma
The number of participants with current asthma in the combined random and symptomatic sample
(n=5391) was 516 (9.6%) in ECRHS I, 720 (13.4%) in ECRHS II and 856 (15.9%) in ECRHS III. Of these,
369 had persistent asthma. Approximately three out of four subjects with persistent asthma reported
having used medication for asthma in the last 12 months in all three surveys, but there was a significant
increase in the use of LABAs, ICSs and LTRAs, and a decreased use of SABAs and theophylline (table 3).
Of the participants with persistent asthma, 17 (4.6%) had physician-diagnosed COPD. Excluding these
participants had only a minor effect on the prevalence of pharmacological treatment. The prevalence of
ICS use in ECRHS III decreased from 49.1% to 48.5% and the corresponding values for SABAs were from
58.0% to 57.4%.
The proportion of adults with asthma who reported regular use of ICSs increased (table 3). This increase
was from 21.5% to 41.8% when excluding asthmatic subjects without self-reported asthma attacks.
Changes in regular use of ICSs between ECRHS I and III by country are presented in figure 4. No
significant heterogeneity between countries was found.
Asthma attacks decreased throughout the study, whereas hospitalisations and the proportion of
participants who reported having seen at doctor for their breathing problem in the last 12 months
remained stable (table 3).
TABLE 2 Prevalence of current asthma and use of medication for asthma in the random
sample at European Community Respiratory Health Survey III per participating country
Subjects Current asthma SABA LABA# ICS# Any medication
Iceland 347 12.4 8.4 5.7 5.4 11.2
Norway 330 12.2 8.0 5.9 5.9 12.1
Sweden 717 9.8 7.8 4.0 6.7 10.7
Estonia 105 7.6 2.9 4.8 7.6 8.6
Belgium 286 3.5 1.5 3.6 4.9 5.6
Germany 377 11.4 3.6 4.4 8.0 8.8
France 889 12.3 7.1 4.7 6.8 12.5
UK 249 13.3 12.4 2.0 3.6 12.8
Italy 226 9.7 4.0 0 4.0 6.6
Spain 872 7.9 3.7 3.6 4.6 6.7
Australia 219 16.9 10.7 8.0 8.5 15.5
p-value <0.0001 <0.0001 0.003 0.13 <0.0001
Data are presented as n, unless otherwise stated. SABA: short-acting b2-agonist; LABA: long-acting
b2-agonist; ICS: inhaled corticosteroid.
#: as single inhalers or in combination.
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FIGURE 3 Ecological analysis of the association between prevalence of current asthma and the use of mediation for asthma in each country: a)
any asthma medication and b) inhaled corticosteroids.
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Variables associated with the regular use of ICSs
Using ICSs on a regular basis in the participants with persistent asthma was related to having had asthma
attacks and having been seen by a doctor in the last 12 months (table 4). There was also an association of
borderline statistical significance between higher age and regular use of ICSs (p=0.06).
Discussion
The main finding in the present analysis was an increase in the use of medication for asthma (e.g. ICSs
and LABAs) in the general population during the 20-year follow-up period. Among those with persistent
TABLE 3 Use of medication, asthma attacks and healthcare utilisation during the last 12 months in subjects with persistent
asthma#
ECRHS I ECRHS II ECRHS III Change in prevalence
Inhaled SABA 68.6 67.5 58.0 −10.1 (−15.5–−4.7)
Inhaled LABAs¶ 14.8 40.4 25.3 (19.5–31.1)
ICSs¶ 31.4 46.2 49.1 17.2 (11.6–22.9)
ICSs used daily in the last 3 months 18.8 26.3 32.8 13.5 (8.6–18.3)
ICS+LABA 12.7 36.4 23.5 (17.9–29.0)
Inhaled anticholinergics 2.6 2.3 3.7 1.0 (−1.5–3.4)
Theophylline 13.0 2.9 0.3 −12.5 (−15.9–9.1)
Oral b2-agonists 7.5 1.7 0 −7.5+
LTRAs 3.3 7.1 3.7 (0.07–6.7)
OCSs 8.8 9.1 6.7 −1.6 (−5.1–1.9)
Any medication for asthma 72.9 76.9 73.9 1.2 (3.2–5.7)
Hospitalisations 2.2 1.5 1.2 −1.1 (−3.0–0.8)
At least one asthma attack in the last 12 months 68.8 51.0 40.9 −27.9 (−33.7–−22.1)
Three or more asthma attacks in the last 12 months 46.5 35.8 25.8 −20.8 (−26.5–−15.0)
Doctor visit for breathing problems in the last 12 months 41.7 34.3 42.3 0.6 (−5.7–6.9)
Data are presented as % or % (95% CI). ECRHS: European Community Respiratory Health Survey; SABA: short-acting b2-agonist; LABA:
long-acting b2-agonist; ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist; OCS: oral corticosteroid.
#: n=369; ¶: as a single
inhaler or in combination; +: not possible to calculate 95% confidence interval.
Overall  (I2=0.0%, p=0.632)
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FIGURE 4 Change in the regular use of inhaled corticosteroids (as a single inhaler or in combination; any use
in the last 12 months) in participants with persistent asthma analysed by country and combined in a
meta-analysis. Analysis was not possible for Estonia due to the limited number of participants. The area of
each square is proportional to the reciprocal of the variance of the estimate for the country. The combined
random effects estimate is shown by the dashed line; the width of the diamond is the 95% confidence interval.
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asthma there has been a reduction in asthma attacks, suggesting an improvement of asthma control.
However, two-thirds of adults with persistent asthma did not take ICSs regularly, 40% reported having at
least one asthma attack and less than half had seen a doctor because of their breathing problem in the last
year.
In the present study a third of the participants with persistent asthma were using ICSs on a regular basis at
the second follow-up. This is almost a doubling proportion compared with the first survey in 1991–1994 [13],
but still a surprisingly low figure given that the regular use of ICSs is recommended in all adults with
asthma except in those with infrequent asthma symptoms [1, 24]. An increased use of ICSs over time is in
accordance with data from a large Canadian registry study [25], but our findings also reflect those of the
1999 AIRE (Asthma insights and reality in Europe) study which reported low ICS use in asthma [4]. A low
usage of ICSs on a daily basis was also reported in the REALISE (Recognise asthma and link to symptoms
and experience) study, where over half of the participants on preventer therapy reported using this less
than daily [16]. AIRE and REALISE also showed a high prevalence of uncontrolled asthma, a finding that
has been replicated in several other studies [2, 3]. A positive aspect is that we found a decrease in reported
asthma attacks, which suggests an improvement in asthma control; even in the present study 40% of those
with persistent asthma reported having had at least one asthma attack in the last year. This result is in
accordance with a recent report from a Canadian study [26], but in contrast with some previous studies
reporting that the level of asthma control is not improving over time [2, 27, 28]. One reason for this is that
this is a cohort study, and we are therefore looking at both temporal and age-related changes.
Several new types of drugs have been introduced during the follow-up time of the ECRHS. LABAs are now
used by two-thirds of those using ICSs in ECRHS III. The addition of LABAs to ICSs has been shown to
decrease exacerbations and improve symptom control in asthmatic subjects that are not well controlled
with ICSs alone [29]. However, there are also data indicating that the ICS+LABA combination is used in
some patients that could be controlled with ICSs alone [30]. Treatment with LTRAs has also been shown
to improve asthma control when added to ICSs in patients with uncontrolled asthma [31]. LTRAs are
included in international guidelines as an alternative to LABAs [1]. Despite this we found that LTRAs had
been used in less than one out of 10 of the adults with asthma in ECRHS III. The use of theophylline and
oral β2-agonists has almost disappeared during this 20-year study period. Anticholinergics were used only
by a small number of patients, which is expected as tiotropium was introduced in asthma guidelines in
2015 [32]. None of the participants reported using omalizumab or anti-IL-5 treatment.
At the first ECRHS survey large differences were found regarding the prevalence of use of ICSs among
countries [13]. This difference is much lower now and, in fact, no longer statistically significant. This
change might be related to the fact that the Global Initiative for Asthma (GINA) guidelines [1] as well as
national guidelines [33] have been implemented in most countries. As in our previous analyses of ECRHS,
we found the highest prevalence of current asthma and use of medication for asthma was in Australia [13].
There was a strong correlation between the prevalence of asthma and the prevalence of use of any
medication for asthma in the ECRHS countries. This was, however, not the case for the prevalence of ICS
use, indicating that factors other than asthma prevalence may play a role in how much ICS is used in a
country. These factors may include national guidelines, different views on the risk of ICS-related
side-effects and differences how the healthcare system is organised in the different countries.
Having seen a doctor for breathing problems increased the likelihood of regular ICS use. However, in the
present study only ∼40% of the adults with asthma had seen a doctor in the last year for breathing
TABLE 4 Predictors of regular use of inhaled corticosteroids in participants with persistent
asthma#
Crude OR (95% CI) Adjusted OR (95% CI)¶
Female 2.16 (1.09–4.28) 1.61 (0.81–3.13)
Age at baseline (per 10 year) 1.59 (0.97–2.61) 1.61 (0.98–2.64)
BMI (per 5 units) 1.69 (1.20–2.38) 1.23 (0.87–1.75)
Current smoking 0.38 (0.17–0.85) 0.89 (0.38–2.09)
Low educational level 1.61 (0.51–5.04) Not included
Asthma attack in the last 12 months 2.09 (1.23–3.55) 2.56 (1.37–4.79)
Doctor visit in the last 12 months 4.27 (2.51–7.27) 3.58 (1.96–6.55)
Hospitalisation in the last 12 months 9.76 (0.63–150) Not included
BMI: body mass index. #: n=369; ¶: adjusted for the variables in the table, survey and country.
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problems. These results are in accordance with those from a recent study that also showed that most
asthmatic subjects in Sweden lacked regular healthcare contacts [34]. The results of the present study
suggest that having regular follow-ups in patients with asthma may be a way of improving treatment in
asthma. This is probably related to increased adherence, as regular healthcare consultations was the
strongest predictor for increased adherence between ECRHS I and II in a previous analysis [35]. An
alternative way of interpreting our results is that patients with more frequent symptoms tend to use
asthma drugs more frequently and require more frequent doctor visits. This interpretation is supported by
the fact that the other factor that was related to regular ICS use was having had asthma attacks, which is
what is to be expected as ICSs are often used to decrease the risk of further asthma attacks. In analyses of
ECRHS I and II we have previously reported that current smokers with asthma were less likely to be using
asthma medications [15], and to have started using ICSs between the first and second survey [14]. This
was also found in the unadjusted analysis in the present study, but the association was not significant after
adjusting for other variables such as doctor visits and asthma attacks. In the same way, we found that
females were more likely to use ICSs than males in the unadjusted analyses [14, 15], but this association
also became nonsignificant in the adjusted model. In the present analysis there was a borderline significant
association between regular use of ICSs and higher age. This finding is in accordance with some previous
studies showing a higher adherence to use of ICSs in older patients [36, 37].
The present study is unique in that we were able to follow a large population sample for 20 years. The
methodology used in the three surveys was identical and this, together with the large sample size, is a
major strength of the study. A weakness is that we lost a relatively large proportion of those investigated in
the first survey. The nonparticipants were somewhat younger, and more likely to be smokers and to use
SABAs. Another weakness is that we fully rely on self-reported data. The number of participants from
each country was small and therefore the geographical variation shown in the study may not necessarily
give an accurate picture of the geographical pattern in asthma treatment. As the participants are selected
from the general population, most participants with asthma will have mild asthma and the study therefore
gives little information on treatment with severe asthma. In the study we used self-reported asthma attacks
as a proxy for asthma control. The reason for this is that the GINA definition of asthma control [1] was
not available at the first survey.
In conclusion, this longitudinal survey shows that the therapeutic management of asthma has changed
over time, with an increase in the use of ICSs and ICS+LABA combinations. There was also a decrease in
reported asthma attacks. Despite this, only one-third of subjects with asthma were regularly using ICSs,
40% reported having at least one asthma attack and less than half had seen a doctor in the last 12 months.
This indicates that underuse of ICSs and lack of regular healthcare remains a problem in the management
of asthma.
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